Farah Z Dourra, PA
Physician Assistant · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 3
- Since medical school
- 7 years
- Graduated 2019
Offices
3 locations · University of California San Francisco · UCSF Medical Group Business Services
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Farah Z Dourra’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$9,132
Medicare paid this office $9,132 for 71 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 28 | $2,216 | $74 |
| New patient visit (45+ min) | 22 | $2,139 | $97 |
| Probing of nasal tear duct | 11 | $1,526 | $139 |
Procedures year by year
| Procedure | 2021 | 2022 | 2024 |
|---|---|---|---|
| Probing of nasal tear duct | – | – | 11 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
71 Original Medicare patients in 2024. Average age 74 · Women 59% · Also on Medicaid 25% · Health risk score 1.03. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 55% · Cancer 24% · Diabetes 20% · Chronic kidney disease 20% · Depression 18%.
The office billed $95,628, Medicare allowed $11,633 and paid $9,132; for 96 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 71 | 96 | 74 | 1.03 | $95,628 | $9,132 |
| 2022 | 243 | 303 | 76 | 1.75 | $46,324 | $16,995 |
| 2021 | 198 | 333 | 76 | 1.54 | $35,910 | $18,415 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2022: 6 services
| Return visit (30+ min) | 86 | $6,030 | $66 |
| Return visit (30+ min) | 37 | $3,243 | $83 |
| Short return visit (20+ min) | 43 | $2,484 | $56 |
| Short return visit (20+ min) | 54 | $2,317 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $740 | $49 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 39 | $379 | $9 |
2021: 4 services
| Short return visit (20+ min) | 142 | $10,114 | $62 |
| Return visit (30+ min) | 59 | $5,743 | $91 |
| Long return visit (40+ min) | 11 | $1,403 | $128 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 83 | $901 | $10 |
Drugs they prescribed that Part D paid
$18,873
Pharmacies billed $18,873 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
155 generic and fewer than 11 brand-name prescriptions · $18,873 in drug cost · 19 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Atorvastatin | 13 | $63 | $5 |
Year by year
| 2024 | 197 | 66 | None | None | $18,873 |
| 2023 | 337 | 124 | None | None | $123,693 |
| 2022 | 451 | 120 | 0% (0) | 16% | $80,319 |
| 2021 | 45 | 15 | 0% (0) | None | $4,464 |
| 2020 | 38 | 13 | None | None | $3,559 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Trelegy Ellipta | 60 | $63,845 | $1,064 |
| Eliquis | 14 | $11,651 | $832 |
| Albuterol Sulfate Hfa | 35 | $1,508 | $43 |
| Atorvastatin | 17 | $354 | $21 |
| Azithromycin | 12 | $235 | $20 |
| Methylprednisolone | 12 | $93 | $8 |
| Furosemide | 14 | $74 | $5 |
2022: 14 drugs
| Eliquis | 23 | $25,019 | $1,088 |
| Entresto | 12 | $14,573 | $1,214 |
| Metoprolol | 42 | $1,666 | $40 |
| Atorvastatin | 35 | $812 | $23 |
| Bisoprolol | 11 | $701 | $64 |
| Potassium Chloride | 13 | $636 | $49 |
| Amiodarone | 11 | $542 | $49 |
| Clopidogrel | 24 | $485 | $20 |
| Losartan | 34 | $418 | $12 |
| Nitroglycerin | 24 | $316 | $13 |
| Furosemide | 43 | $253 | $6 |
| Spironolactone | 19 | $192 | $10 |
| Isosorbide Mononitrate Er | 14 | $165 | $12 |
| Lisinopril | 22 | $75 | $3 |
Money from drug and device companies
$311 in 2024
| 2024 | 1 | 4 | None | $311 |
| 2023 | 5 | 7 | None | $390 |
| 2022 | 12 | 36 | None | $530 |
| 2021 | 14 | 76 | None | $1,254 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $311 | 4 payments
|
See all 4 published payments
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2024-12-17 | Lifevest | $93 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2024-10-24 | Lifevest | $96 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2024-10-10 | Lifevest | $26 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2024-03-25 | Lifevest | $96 |
See earlier years (2023, 2022, 2021)
2023: $390
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $190 | 3 payments
|
| GlaxoSmithKline | None | $125 | 1 payment
|
| Kestra Medical Technology Services | Assure Wcd | $37 | 1 payment
|
| Boston Scientific | Varithena Administration Pack | $22 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $16 | 1 payment
|
2022: $530
| Janssen Pharmaceuticals | Xarelto | $173 | 14 payments
|
| Merck Sharp & Dohme | Verquvo | $97 | 6 payments
|
| Amarin Pharma | Vascepa | $51 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $47 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $38 | 3 payments
|
| Boston Scientific | Watchman Access System | $27 | 1 payment
|
| OptiNose US | Xhance | $22 | 1 payment
|
| Novo Nordisk | Ozempic | $17 | 1 payment
|
| Amgen | Repatha | $17 | 1 payment
|
| Impulse Dynamics (USA) | Optimizer | $15 | 1 payment
|
| Pfizer | Vyndaqel | $13 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $13 | 1 payment
|
2021: $1,254
| Janssen Pharmaceuticals | Xarelto | $477 | 35 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $136 | 2 payments
|
| Amarin Pharma | Vascepa | $119 | 8 payments
|
| Amgen | Repatha | $118 | 7 payments
|
| Novartis Pharmaceuticals | Entresto | $101 | 7 payments
|
| Actelion Pharmaceuticals US | Opsumit | $90 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $66 | 5 payments
|
| Regeneron Healthcare Solutions | Evkeeza | $35 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $35 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $20 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $17 | 1 payment
|
| Chiesi USA | Kengreal | $17 | 1 payment
|
| Lundbeck | Northera | $11 | 1 payment
|
| United Therapeutics | Orenitram | $11 | 1 payment
|
Professional record
- NPI
- 1467016675
- Licence
- CA 62460
- Group
- University of California San Francisco · UCSF Medical Group Business Services
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2019-04-24
- NPI last updated
- 2023-09-14
- NPI record certified
- 2023-09-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 20200 Outer Dr, Dearborn, MI, 48124 · 5325 Elliott Dr Fl 2, Ypsilanti, MI, 48197